IQVIQVIA HOLDINGS INC.

NYSE iqvia.com


$ 214.46 $ 0.61 (0.28 %)    

Tuesday, 18-Jun-2024 09:53:03 EDT
QQQ $ 484.53 $ -0.67 (-0.14 %)
DIA $ 389.41 $ 0.60 (0.15 %)
SPY $ 547.63 $ 0.41 (0.07 %)
TLT $ 93.97 $ 0.03 (0.03 %)
GLD $ 215.12 $ 0.93 (0.43 %)
$ 213.32
$ 213.85
$ 0.00 x 0
$ 0.00 x 0
$ 213.85 - $ 214.84
$ 167.42 - $ 261.73
1,014,155
na
39.31B
$ 1.40
$ 28.97
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-15-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-15-2023 12-31-2022 10-K
7 10-27-2022 09-30-2022 10-Q
8 07-22-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 10-22-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-23-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-K
15 10-22-2020 09-30-2020 10-Q
16 07-23-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-18-2020 12-31-2019 10-K
19 11-01-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 10-25-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 02-16-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 07-27-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-11-2016 12-31-2015 10-K
35 10-28-2015 09-30-2015 10-Q
36 07-29-2015 06-30-2015 10-Q
37 04-29-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-K
39 10-30-2014 09-30-2014 10-Q
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abbvie-amazon-goldman-sachs-and-2-major-health-care-stocks-on-cnbcs-final-trades

AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners.

 goldman-sachs-initiates-coverage-on-iqvia-hldgs-with-buy-rating-announces-price-target-of-270

Goldman Sachs analyst Matthew Sykes initiates coverage on IQVIA Hldgs (NYSE:IQV) with a Buy rating and announces Price Targe...

 evercore-isi-group-maintains-outperform-on-iqvia-hldgs-lowers-price-target-to-250

Evercore ISI Group analyst Elizabeth Anderson maintains IQVIA Hldgs (NYSE:IQV) with a Outperform and lowers the price target...

 truist-securities-maintains-buy-on-iqvia-hldgs-lowers-price-target-to-292

Truist Securities analyst Jailendra Singh maintains IQVIA Hldgs (NYSE:IQV) with a Buy and lowers the price target from $297 ...

 baird-maintains-neutral-on-iqvia-hldgs-lowers-price-target-to-245

Baird analyst Eric Coldwell maintains IQVIA Hldgs (NYSE:IQV) with a Neutral and lowers the price target from $254 to $245.

 iqvia-lowers-fy24-outlook-revenue-15325b---15575b-down-from-1540b---1560b-vs-1553b-estimate-reaffirm-adj-eps-outlook-1095---1125-vs-111-estimate

Full-Year 2024 Guidance The company reaffirms its full-year revenue guidance on a constant currency basis. After adjusting fo...

 iqvia-hldgs-q1-2024-adj-eps-254-beats-248-estimate-sales-3737b-beat-3699b-estimate

IQVIA Hldgs (NYSE:IQV) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $2.48 by 2.4...

 salesforce--iqvia-expand-partnership-life-sciences-cloud-gets-a-superpower-boost

Salesforce shares rise after partnership with IQVIA to develop Life Sciences Cloud for customer engagement.

Core News & Articles

IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Sale...

 truist-securities-maintains-buy-on-iqvia-hldgs-raises-price-target-to-297

Truist Securities analyst Jailendra Singh maintains IQVIA Hldgs (NYSE:IQV) with a Buy and raises the price target from $286 ...

 leerink-partners-initiates-coverage-on-iqvia-hldgs-with-outperform-rating-announces-price-target-of-290

Leerink Partners analyst Michael Cherny initiates coverage on IQVIA Hldgs (NYSE:IQV) with a Outperform rating and announces ...

 guggenheim-downgrades-iqvia-hldgs-to-neutral

Guggenheim analyst Sandy Draper downgrades IQVIA Hldgs (NYSE:IQV) from Buy to Neutral.